Li, J., Wang, Z., Zhang, Y., Tan, J., Li, R., Jiang, H., Qu, S., Li, P. (2026). Neoadjuvant PD-1 inhibitor plus paclitaxel, pingyangmycin, and platinum-based chemotherapy (4P therapy) as a bladder-sparing strategy for high-risk non–muscle-invasive/muscle-invasive bladder cancer: A retrospective cohort study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16606